| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| November 17th, 2008 | 24 | Yes |
Popular Name: PP121 PP121
Find On: PubMed — Wikipedia — Google
CAS Numbers: 1092788-83-4 , [1092788-83-4]
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.24 | 8.08 | -10.14 | 3 | 7 | 0 | 98 | 319.372 | 2 | ↓ |
| Lo Low (pH 4.5-6) | 2.24 | 8.38 | -34.95 | 4 | 7 | 1 | 100 | 320.38 | 2 | ↓ |
| Lo Low (pH 4.5-6) | 2.24 | 4 | -34.3 | 4 | 7 | 1 | 100 | 320.38 | 2 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 8.14e-02 g/l | DrugBank-experimental |
| Target | DNA-PK, mTOR, PDGF | Selleck Chemicals |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ABL1-1-E | Tyrosine-protein Kinase ABL (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.51 | Binding ≤ 10μM |
| BCR-1-E | Breakpoint Cluster Region Protein (cluster #1 Of 1), Eukaryotic | Eukaryotes | 18 | 0.45 | Binding ≤ 10μM |
| EGFR-1-E | Epidermal Growth Factor Receptor ErbB1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 260 | 0.38 | Binding ≤ 10μM |
| EPHB4-1-E | Ephrin Type-B Receptor 4 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 190 | 0.39 | Binding ≤ 10μM |
| HCK-1-E | Tyrosine-protein Kinase HCK (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8 | 0.47 | Binding ≤ 10μM |
| MTOR-2-E | Serine/threonine-protein Kinase MTOR (cluster #2 Of 3), Eukaryotic | Eukaryotes | 10 | 0.47 | Binding ≤ 10μM |
| PI4KB-1-E | PI4-kinase Beta Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 60 | 0.42 | Binding ≤ 10μM |
| PK3CA-2-E | PI3-kinase P110-alpha Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 52 | 0.42 | Binding ≤ 10μM |
| PK3CB-2-E | PI3-kinase P110-beta Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 1400 | 0.34 | Binding ≤ 10μM |
| PK3CD-2-E | PI3-kinase P110-delta Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 150 | 0.40 | Binding ≤ 10μM |
| PK3CG-2-E | PI3-kinase P110-gamma Subunit (cluster #2 Of 3), Eukaryotic | Eukaryotes | 1100 | 0.35 | Binding ≤ 10μM |
| PRKDC-1-E | DNA-dependent Protein Kinase (cluster #1 Of 1), Eukaryotic | Eukaryotes | 60 | 0.42 | Binding ≤ 10μM |
| RET-1-E | Tyrosine-protein Kinase Receptor RET (cluster #1 Of 1), Eukaryotic | Eukaryotes | 1 | 0.53 | Binding ≤ 10μM |
| SRC-1-E | Tyrosine-protein Kinase SRC (cluster #1 Of 3), Eukaryotic | Eukaryotes | 14 | 0.46 | Binding ≤ 10μM |
| VGFR2-1-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 41 | 0.43 | Binding ≤ 10μM |
| Z81057-4-O | HUVEC (Umbilical Vein Endothelial Cells) (cluster #4 Of 4), Other | Other | 0 | 0.00 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| BCR_HUMAN | P11274 | Breakpoint Cluster Region Protein, Human | 18 | 0.45 | Binding ≤ 1μM |
| PRKDC_HUMAN | P78527 | DNA-dependent Protein Kinase, Human | 60 | 0.42 | Binding ≤ 1μM |
| EPHB4_HUMAN | P54760 | Ephrin Type-B Receptor 4, Human | 190 | 0.39 | Binding ≤ 1μM |
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 260 | 0.38 | Binding ≤ 1μM |
| MTOR_HUMAN | P42345 | FK506 Binding Protein 12, Human | 10 | 0.47 | Binding ≤ 1μM |
| PK3CA_HUMAN | P42336 | PI3-kinase P110-alpha Subunit, Human | 52 | 0.42 | Binding ≤ 1μM |
| PK3CD_HUMAN | O00329 | PI3-kinase P110-delta Subunit, Human | 150 | 0.40 | Binding ≤ 1μM |
| PI4KB_HUMAN | Q9UBF8 | PI4-kinase Beta Subunit, Human | 60 | 0.42 | Binding ≤ 1μM |
| ABL1_HUMAN | P00519 | Tyrosine-protein Kinase ABL, Human | 18 | 0.45 | Binding ≤ 1μM |
| HCK_HUMAN | P08631 | Tyrosine-protein Kinase HCK, Human | 8 | 0.47 | Binding ≤ 1μM |
| RET_HUMAN | P07949 | Tyrosine-protein Kinase Receptor RET, Human | 1 | 0.53 | Binding ≤ 1μM |
| SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 14 | 0.46 | Binding ≤ 1μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 12 | 0.46 | Binding ≤ 1μM |
| BCR_HUMAN | P11274 | Breakpoint Cluster Region Protein, Human | 18 | 0.45 | Binding ≤ 10μM |
| PRKDC_HUMAN | P78527 | DNA-dependent Protein Kinase, Human | 60 | 0.42 | Binding ≤ 10μM |
| EPHB4_HUMAN | P54760 | Ephrin Type-B Receptor 4, Human | 190 | 0.39 | Binding ≤ 10μM |
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 260 | 0.38 | Binding ≤ 10μM |
| MTOR_HUMAN | P42345 | FK506 Binding Protein 12, Human | 10 | 0.47 | Binding ≤ 10μM |
| PK3CA_HUMAN | P42336 | PI3-kinase P110-alpha Subunit, Human | 52 | 0.42 | Binding ≤ 10μM |
| PK3CB_HUMAN | P42338 | PI3-kinase P110-beta Subunit, Human | 1400 | 0.34 | Binding ≤ 10μM |
| PK3CD_HUMAN | O00329 | PI3-kinase P110-delta Subunit, Human | 150 | 0.40 | Binding ≤ 10μM |
| PK3CG_HUMAN | P48736 | PI3-kinase P110-gamma Subunit, Human | 1100 | 0.35 | Binding ≤ 10μM |
| PI4KB_HUMAN | Q9UBF8 | PI4-kinase Beta Subunit, Human | 60 | 0.42 | Binding ≤ 10μM |
| ABL1_HUMAN | P00519 | Tyrosine-protein Kinase ABL, Human | 18 | 0.45 | Binding ≤ 10μM |
| HCK_HUMAN | P08631 | Tyrosine-protein Kinase HCK, Human | 8 | 0.47 | Binding ≤ 10μM |
| RET_HUMAN | P07949 | Tyrosine-protein Kinase Receptor RET, Human | 1 | 0.53 | Binding ≤ 10μM |
| SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 14 | 0.46 | Binding ≤ 10μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 12 | 0.46 | Binding ≤ 10μM |
| Z81057 | Z81057 | HUVEC (Umbilical Vein Endothelial Cells) | 0.31 | 0.55 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| Antigen activates B Cell Receptor (BCR) leading to generation of second messenge | |
| CD28 dependent PI3K/Akt signaling | |
| CDO in myogenesis | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| Costimulation by the CD28 family | |
| Cytosolic sensors of pathogen-associated DNA | |
| DAP12 signaling | |
| Downstream signal transduction | |
| Downstream TCR signaling | |
| EGFR downregulation | |
| EGFR interacts with phospholipase C-gamma | |
| EGFR Transactivation by Gastrin | |
| EPH-ephrin mediated repulsion of cells | |
| EPH-Ephrin signaling | |
| EPHA-mediated growth cone collapse | |
| EPHB-mediated forward signaling | |
| Ephrin signaling | |
| Factors involved in megakaryocyte development and platelet production | |
| FCGR activation | |
| G alpha (12/13) signalling events | |
| G alpha (q) signalling events | |
| G beta:gamma signalling through PI3Kgamma | |
| GAB1 signalosome | |
| GPVI-mediated activation cascade | |
| GRB2 events in EGFR signaling | |
| GRB2 events in ERBB2 signaling | |
| HSF1-dependent transactivation | |
| Integrin cell surface interactions | |
| Interleukin receptor SHC signaling | |
| Interleukin-3, 5 and GM-CSF signaling | |
| IRF3-mediated induction of type I IFN | |
| mTOR signalling | |
| Nef and signal transduction | |
| Nephrin interactions | |
| Neurophilin interactions with VEGF and VEGFR | |
| Nonhomologous End-joining (NHEJ) | |
| PI-3K cascade | |
| PI3K Cascade | |
| PI3K events in ERBB2 signaling | |
| PI3K events in ERBB4 signaling | |
| PI3K/AKT activation | |
| PIP3 activates AKT signaling | |
| PLCG1 events in ERBB2 signaling | |
| Processing of DNA ends prior to end rejoining | |
| Regulation of actin dynamics for phagocytic cup formation | |
| Regulation of signaling by CBL | |
| Release of eIF4E | |
| Rho GTPase cycle | |
| Role of Abl in Robo-Slit signaling | |
| Role of LAT2/NTAL/LAB on calcium mobilization | |
| Role of phospholipids in phagocytosis | |
| S6K1-mediated signalling | |
| SHC1 events in EGFR signaling | |
| SHC1 events in ERBB2 signaling | |
| Signal transduction by L1 | |
| Signaling by constitutively active EGFR | |
| Signaling by EGFR | |
| Signaling by ERBB2 | |
| Signaling by ERBB4 | |
| Signaling by FGFR mutants | |
| Signaling by FGFR1 fusion mutants | |
| Signaling by SCF-KIT | |
| Synthesis of PIPs at the Golgi membrane | |
| Synthesis of PIPs at the plasma membrane | |
| Tie2 Signaling | |
| VEGF binds to VEGFR leading to receptor dimerization | |
| VEGFA-VEGFR2 Pathway | |
| VEGFR2 mediated cell proliferation | |
| VEGFR2 mediated vascular permeability |
No pre-computed analogs available. Try a structural similarity search.